Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1(G93A) and NSG animal models. ‘Reprogrammed’ stem cells to treat spinal-cord injuries for the first time. Japan poised to allow ‘reprogrammed’ stem-cell therapy for damaged corneas. ‘Reprogrammed’ stem cells implanted into patient with Parkinson’s disease. Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction. Transplantation of human embryonic stem cell-derived retinal pigment epithelial cells in macular degeneration. ![]() Autologous induced stem-cell–derived retinal cells for macular degeneration. A bioengineered retinal pigment epithelial monolayer for advanced, dry age-related macular degeneration. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt’s macular dystrophy: follow-up of two open-label phase 1/2 studies. Embryonic stem cell trials for macular degeneration: a preliminary report. Embryonic stem cell pioneer Geron exits field, cuts losses. Current status of pluripotent stem cells: moving the first therapies to the clinic. SnapShot: directed differentiation of pluripotent stem cells. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Embryonic stem cell lines derived from human blastocysts. Long-term safety of human retinal progenitor cell transplantation in retinitis pigmentosa patients. Immortalized human fetal retinal cells retain progenitor characteristics and represent a potential source for the treatment of retinal degenerative disease. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson’s disease. Long-term clinical outcome of fetal cell transplantation for Parkinson disease: two case reports. Fetal stem cell transplantation: past, present, and future. Transplantation of fetal substantia nigra and adrenal medulla to the caudate nucleus in two patients with Parkinson’s disease. MSC-based product characterization for clinical trials: an FDA perspective. ![]() Mesenchymal stromal cells: clinical challenges and therapeutic opportunities. Clinical trials with mesenchymal stem cells: an update. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. Supralethal whole body irradiation and isologous marrow transplantation in man. Principles of Regenerative Medicine 3rd edn, (Academic, 2019). Here, we review these engineering approaches and areas in which they will help broaden the utility and clinical applicability of stem cells.Ītala, A., Lanza, R., Mikos, T., Nerem, R. Moreover, gene therapy and gene editing technologies are being used to create stem cell derivatives with improved functionality, specificity and responsiveness compared with their natural counterparts. These next-generation stem cells are being used as ‘Trojan horses’ to improve the delivery of drugs and oncolytic viruses to intractable tumours and are also being engineered with angiogenic, neurotrophic and anti-inflammatory molecules to accelerate the repair of injured or diseased tissues. ![]() However, the advent of cell-engineering approaches is ushering in a new generation of stem cell-based therapies, greatly expanding their therapeutic utility. This has primarily involved the transplantation of primary cells such as haematopoietic and mesenchymal stem cells and, more recently, derivatives of pluripotent stem cells. Naturally occurring stem cells isolated from humans have been used therapeutically for decades.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |